[IBB] iShares Nasdaq Biotechnology Index Fund

Overview

Type of security: Fund

Tags: Biotech, Country, Equity, ETF, Health, Health care, Healthcare, Index Based, Not Inversed, Sector, Stocks, U.S., Unleveraged

The data is delayed by 15 minutes.

 

Price: 272.32 Change: 5.62 (2.11%)
Ext. hours: 274.4 Change: 2.08 (0.76%)

chart IBB

Refresh chart

Strongest Trends Summary For IBB

IBB is in the medium-term up 17% in 1 month and down -10% in 5 months. In the long-term up 63% above S&P in 20 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

See how to gain 20% in 14 sec with TrendsInvesting

Technical Data
High 52 week122.16 Low 52 week96.21 Last close96.21 Last change-2.14%
RSI23.11 Average true range3.24 Beta0.99 Volume1.25 M
Simple moving average 20 days-7.65% Simple moving average 50 days-9.54% Simple moving average 200 days-13.16%
Performance Data
Performance Week-8.79% Performance Month-8.42% Performance Quart-18.21% Performance Half-15.41%
Performance Year-9.31% Performance Year-to-date-9.76% Volatility daily1.62% Volatility weekly3.62%
Volatility monthly7.43% Volatility yearly25.72% Relative Volume180.65% Average Volume2.11 M
New High New Low
Funds Characteristics
30-day SEC yield Average market capitalization Average weighted market capitalization Forward P/E
Gross expense ratio Index dividend yield Median market cap Number of holdings0
Price to Book Value 9.9 Price to Earnings40.91 Total expense ratio0.48% Total net assets4.92 B
Weighted market capitalization

Info

Characteristics:
NAME VALUE
Total Expense Ratio0,48
Number Of Holdingsn/a
Total Net Assets4 915 409 116,00
P/E Ratio40,91
P/Bv Ratio9,9
Top Holdings:
NAME VALUE
Amgen Inc8,91
Biogen Idec Inc8,04
Celgene Corp7,78
Gilead Sciences Inc7,67
Alexion Pharmaceuticals Inc6,78
Regeneron Pharmaceuticals Inc4,04
Mylan Inc3,93
Vertex Pharmaceuticals Inc3,92
Illumina Inc3,88
Biomarin Pharmaceutical Inc2,36
Sector Breakdown:
NAME VALUE
Biotechnology78,14
Pharmaceuticals21,85
S-t Securities0,04

News

2019-01-17 09:10:00 | Lipocine's stock rockets on premarket leading volume after upbeat liver fat study results

2019-01-17 07:13:02 | Trade of the Day: The Biotechnology Stocks ETF Is Running Out of Steam

2019-01-16 12:26:40 | Aptinyx Stock Plunged 70% after Clinical Trial Failure

2019-01-16 09:19:00 | Aptinyx stock falls 67% after phase 2 trial fails to meet primary endpoint

2019-01-11 10:59:27 | Why Sarepta Therapeutics Stock Is Starting to Shine Again

2019-01-11 08:30:00 | Bear market in value stocks is ending, Wells Fargo predicts a 2019 comeback

2019-01-08 08:00:00 | Two ways to play the biotech boom

2019-01-08 07:24:00 | Biotech's breaking out, and here's why some market experts think an even bigger rally is ahead

2019-01-07 15:02:25 | Three Healthcare Stocks Rallying Over 10% Today

2019-01-07 13:27:00 | Sage Therapeutics's stock shoots higher after postpartum depression treatment's positive trial results

2019-01-07 13:27:00 | Sage Therapeutics's stock shoots higher after postpartum depression treatment's positive trial results

2019-01-07 12:53:00 | ETF Edge, January 7, 2019

2019-01-07 12:26:00 | ETF Edge: Biotech breakout

2019-01-07 08:23:00 | Axsome's stock nearly triples on heavy volume after positive trial of depression treatment

2019-01-04 16:35:00 | Insmed stock shoots up 18% after company says it expects drug Arikayce to bring in $9.8 million in fourth quarter

2019-01-04 10:01:03 | Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus

2019-01-04 07:13:00 | Mersana to discontinue development of one cancer treatment to focus on another

2018-12-31 09:00:22 | Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

2018-12-31 08:52:00 | Heron stock up 4.3% after opioid alternative granted priority review designation from FDA

2018-12-30 15:27:08 | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

2018-12-26 14:22:32 | 6 Valuable Pipeline Drugs With Upcoming Catalysts

2018-12-20 16:42:00 | Mirati Therapeutics Added To NASDAQ Biotechnology Index

2018-12-18 12:25:15 | Is iShares NASDAQ Biotechnology Index ETF IBB A Good Stock To Buy?

2018-12-18 09:43:46 | Best ETFs of 2019: Financial Select Sector SPDR Fund Will Rise Again

2018-12-17 07:00:03 | Market Morning: Rate Hike Ahead, Obamacare Struck Down, JNJ Asbestos Scandal, Qatar Challenges Saudis

2018-12-13 07:32:12 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2018-12-12 03:17:08 | The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen

2018-12-11 15:32:14 | Trump Foreshadows a Bleak Outlook for Biotech IBB, BIB

2018-12-10 09:24:18 | IBB’s $100 Support Level Goes Back to 2017

2018-12-07 11:48:00 | Shares of Moderna open at $22, 4% lower than IPO price

2018-12-04 14:08:00 | Revance Therapeutics reaches licensing agreement with Fosun Pharmaceutical over botox formulation RT002

2018-11-26 07:07:00 | Zafgen's IND for diabetes treatment placed on hold by FDA

2018-11-21 14:17:10 | Pfizer Stock Has Multiple Positive Catalysts

2018-11-21 09:47:02 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2018-11-20 14:03:48 | 7 Biotech ETFs to Consider for 2019

2018-11-16 11:00:38 | uniQure Stock Rose 35.7% Yesterday—Here’s Why

2018-11-13 09:40:02 | Jazz Pharmaceuticals: A Financial Overview in November

2018-11-11 09:10:10 | The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

2018-11-09 15:17:51 | How Marijuana-Focused Biotech Companies Have Performed in 2018

2018-11-08 05:28:00 | Drug prices may be rising, but you can buy biotech stocks at rock-bottom levels

2018-11-07 15:56:29 | Trump was Wrong about the Market

2018-11-07 09:55:00 | MiMedx stock plunges after receiving delisting notice from Nasdaq

2018-11-06 17:50:02 | How Exelixis’s Cabozantinib Franchise Is Positioned in November

2018-11-02 17:18:38 | Stocks finish lower after a volatile trading session

2018-11-02 17:12:51 | Newman: GOP still trying to kill the Affordable Care Act

2018-11-02 08:52:00 | Puma Biotechnology's stock plunges to pace premarket losers after key drug Nerlynx disappoints

2018-11-01 16:09:38 | Small Cap Stocks, Chips Lead Broad Gains, But This Group Surprisingly Lags

2018-10-30 15:50:49 | Why Incyte’s Q3 2018 Earnings Beat Revenue Estimates

2018-10-30 08:02:58 | Shire’s Q3 2018 Earnings: Analyst Estimates

2018-10-25 17:41:00 | Technician reacts to Gilead earnings and the biotech spac...